Pricing Log in Create free account
Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−17.1%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.54 0.16 −0.16%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Lantheus Holdings, Inc. (LNTH) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Lantheus Holdings, Inc. (LNTH) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 0.0× (June 2015) to 9.2× (June 2022); the current reading is higher than 71% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.0× (19.95%)
FY2024 3.8× 18.83%
FY2023 3.2× (17.02%)
FY2022 3.9× (18.91%)
FY2021 4.8× 86.08%
FY2020 2.6× (1.27%)
FY2019 2.6× 18.51%
FY2018 2.2× (25.60%)
FY2017 2.9× 73.90%
FY2016 1.7× 21.79%

Quarterly newest first

Period EV/Sales Change
Sep 2026 4.1× (11.71%)
Jun 2026 4.6× 43.71%
Mar 2026 3.2× 5.65%
Dec 2025 3.0× 28.03%
43 more quarters

Against its own ten years

Low 0.0× High 9.2×
Ten-year median 3.1×
Current reading's percentile 70

EV/Sales against peers

Company EV/Sales
HIMS Hims & Hers Health, Inc. compare 2.4×
SUPN Indivior Pharmaceuticals Inc. compare 2.9×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.0×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
LNTH Lantheus Holdings, Inc. 4.1×
ALKS Alkermes plc compare 4.7×
KNSA Kiniksa Pharmaceuticals International, plc compare 6.7×
LQDA Liquidia Corporation compare 8.6×
AMLX Amylyx Pharmaceuticals, Inc. compare 32.5×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LNTH